Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
L-Arginine Hydrochloride; L-Lysine Hydrochloride
NOVARTIS (SINGAPORE) PTE LTD
V03AF11
INFUSION, SOLUTION
L-Arginine Hydrochloride 25 g/L; L-Lysine Hydrochloride 25 g/L
INTRAVENOUS
Prescription Only
LABORATOIRE BIOLUZ
ACTIVE
2020-08-31
_________________________________________________________________________________ Lysakare Aug 2019.SINv1 Page 1 of 7 1 TRADENAME LysaKare ® 25 g/25 g solution for infusion 2 DESCRIPTION AND COMPOSITION PHARMACEUTICAL FORM Solution for infusion (infusion). Clear, colorless solution, free from visible particles. pH: 5.1 to 6.1 Osmolality: 420 to 480 mOsm/kg ACTIVE SUBSTANCES One 1,000 mL infusion bag contains 25 g of L-arginine hydrochloride (equivalent to 20.7 g arginine) and 25 g of L-lysine hydrochloride (equivalent to 20 g lysine). EXCIPIENTS Water for injections. 3 INDICATIONS LysaKare is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults. 4 DOSAGE REGIMEN AND ADMINISTRATION Since LysaKare is indicated for administration during PRRT with lutetium (177Lu) oxodotreotide, it should only be administered by a healthcare provider experienced in the use of PRRT. Please refer to full prescribing information of lutetium (177Lu) oxodotreotide. DOSAGE REGIMEN GENERAL TARGET POPULATION ADULTS The recommended treatment regimen in adults consists of infusion of a full bag of LysaKare concomitantly with lutetium (177Lu) oxodotreotide. The dose of LysaKare should not be decreased even if the dose of lutetium (177Lu) oxodotreotide is reduced. _________________________________________________________________________________ Lysakare Aug 2019.SINv1 Page 2 of 7 Pre-treatment with an antiemetic is recommended to prevent nausea and vomiting. Antiemetics should be administered with sufficient lead time prior to the start of LysaKare. Please refer to the full prescribing information of the antiemetic for administration instructions. SPECIAL POPULATIONS RENAL IMPAIRMENT Due to the potential for clinical complications related to volume overload and an increase of potassium in blood associated with the use of LysaKare, this product should not be administered in patients with creatinine clearance <30 mL/min. Care should be taken with Lysa Read the complete document